Wei Li

Prof. Wei Li


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2024 in Asian Journal of Surgery
Verified
Journal Article
Open access
WDWeikai Dong
Weikai Dong
ZDZhaoqi Du
Zhaoqi Du
LYLijuan Yang
Lijuan Yang
WLWei Li
Wei Li

12 August 2022 in Asian Journal of Surgery
Verified
Journal Article
Open access
ZDZhaoqi Du
Zhaoqi Du
LYLijuan Yang
Lijuan Yang
HZHanwei Zang
Hanwei Zang
WLWei Li
Wei Li

17 July 2025 in Frontiers in Oncology
Verified
Journal Article
Open access
WDWeikai Dong
Weikai Dong
ZDZhaoqi Du
Zhaoqi Du
DLDianxiao Liu
Dianxiao Liu
LYLijuan Yang
Lijuan Yang
WLWei Li
Wei Li
Introduction: The research into cardiac tumors can be traced back to the 18th century, when Bonet first introduced the relevant concept. It was not until 1936 that the first successful resection of a cardiac tumor was performed. From a pathological origin perspective, cardiac tumors can be categorized into two main types: primary tumors, which originate from the heart itself, and secondary tumors, which result from metastases of malignant tumors in other tissues or organs. Primary cardiac tumors are exceedingly rare, among primary cardiac tumors, roughly 75% are benign, while the remainder are malignant. In contrast, approximately 75% of primary malignant cardiac tumors are sarcomas. Cardiac myxoid fibrosarcoma stands out as a particularly rare diagnosis in this domain.Case report: Case one: A 25-year-old man presented with chest pain and tightness. After initial treatment, his symptoms recurred and worsened. Imaging revealed a large mass in the left atrium obstructing the mitral valve. He underwent surgical resection of the tumor, thrombectomy, and tricuspid valvuloplasty. Pathology diagnosed myxoid fibrosarcoma. The patient was readmitted 7 months later with hemoptysis due to tumor recurrence and was lost to follow-up after symptomatic treatment. Case two: A 67-year-old woman was admitted with cough, chest tightness, and shortness of breath. Physical examination and imaging showed a mass in the left atrium causing mitral valve obstruction. She underwent surgical resection of the tumor. Pathology confirmed myxoid fibrosarcoma. After 6 months of follow-up, there was no tumor recurrence or metastasis.Discussion: Myxoid fibrosarcoma located in the left atrium can lead to mitral valve obstruction, causing symptoms of mitral stenosis such as dyspnea, cough, hemoptysis, and reduced exercise tolerance. Surgery remains the primary treatment for primary left atrial malignant tumors. Once the diagnosis is confirmed, active surgical intervention should be performed to relieve blood flow obstruction, remove pericardial effusion, and alleviate cardiac compression, which can extend patients’ lives in the short term and improve their quality of life. Despite advancements in diagnostic techniques and surgical methods, the prognosis for patients with cardiac tumors still depends on the histology and location of the tumor.

14 June 2024 in Asian Journal of Surgery
Verified
Journal Article
Open access
WDWeikai Dong
Weikai Dong
WLWei Li
Wei Li

11 October 2026 in Research Square
Verified
Preprint
Open access
PDF file
ZLZhaoyang Li
Zhaoyang Li
MYMinghui Yue
Minghui Yue
NGNing Gai
Ning Gai
WLWei Li
Wei Li
Objective:To evaluate the technical feasibility, perioperative safety, and mid-term clinical outcomes of Sheath-Assisted Limited Repair (SALR) in anatomically suitable patients with iatrogenic femoral artery pseudoaneurysms (FAP). Methods: A retrospective cohort analysis was conducted on 10 consecutive patients with iatrogenic FAP who met strict anatomical eligibility criteria and underwent SALR at Binzhou Medical University Hospital between January 2015 and June 2025. Anatomical eligibility was defined as a localized, puncture-related lesion where the arterial defect could be temporarily sealed with an appropriately sized sheath, without involvement of the femoral bifurcation. The primary endpoints were technical success rate, conversion to standard open repair (SOR), reoperation/reintervention, pseudoaneurysm recurrence, and wound-related complications (infection, lymphorrhea). Secondary endpoints included operative time, intraoperative blood loss, bed rest duration, length of stay, and 24-hour postoperative VAS pain scores. Data from 30 patients undergoing SOR were documented for comparative clinical benchmarking. Results: The primary endpoints demonstrated remarkable success in the SALR cohort: the technical success rate was 100% (10/10), with no intraoperative conversions to SOR (0%), zero reinterventions or reoperations, and no recurrence of pseudoaneurysm during a mean follow-up of 24 months. No wound infections or lymphatic leaks occurred (0%). Regarding secondary endpoints, the operative time was 40.5 ± 12.5 min, median intraoperative blood loss was 20 (10, 40) mL, postoperative bed rest was 8.5 ± 2.5 h, and median hospital stay was 3.0 (2.0, 4.0) days. The 24-hour postoperative VAS score was 1.58 ± 0.9. Postoperative ultrasound confirmed 100% patency of the treated arterial segment without stenosis. Conclusion: SALR is a safe, highly feasible, and minimally invasive technique for anatomically suitable iatrogenic FAP. By utilizing the vascular sheath for in situ temporary hemostasis, it completely eliminates the need for extensive vascular dissection and proximal/distal clamping, thereby achieving high technical success, preventing lymphorrhea, and markedly accelerating postoperative recovery.